News >

Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma

Laura Panjwani
Published: Monday, May 16, 2016

Thierry M. Jahan, MD

Thierry M. Jahan, MD

The investigational cancer vaccine CRS-207 may improve response and survival when given with chemotherapy in patients with malignant pleural mesothelioma (MPM) according to results of a phase Ib trial.1

Immunohistochemistry data from 3 patients revealed an increase in tumor-infiltrating lymphocytes (TILs) post–CRS-207. Treatment-associated changes in circulating immune cells and biomarkers were also observed.

The most commonly reported treatment-related adverse events (AEs) include grade 1/2 infusion-related fever, chills/rigors, hypotension, and nausea/vomiting with no treatment-related serious AEs or deaths.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication